Meda Pharms Drug Patent Portfolio

Meda Pharms owns 2 orange book drugs protected by 4 US patents Given below is the list of Meda Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8071073 Compositions comprising azelastine and methods of use thereof 04 Jun, 2028
Active
US8518919 Compositions comprising azelastine and methods of use thereof 22 Nov, 2025
Active
US6024981 Rapidly dissolving robust dosage form 09 Apr, 2018 Expired
US6221392 Rapidly dissolving robust dosage form 09 Apr, 2018 Expired


Given below is the list of recent legal activities going on the following drug patents of Meda Pharms.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 23 May, 2023 US8071073 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 07 Sep, 2021 US9919050
Payment of Maintenance Fee, 8th Year, Large Entity 16 Feb, 2021 US8518919
Payment of Maintenance Fee, 8th Year, Large Entity 30 May, 2019 US8071073 (Litigated)
Post Issue Communication - Certificate of Correction 23 May, 2018 US9919050
Recordation of Patent Grant Mailed 20 Mar, 2018 US9919050
Patent Issue Date Used in PTA Calculation 20 Mar, 2018 US9919050
Email Notification 01 Mar, 2018 US9919050
Issue Notification Mailed 28 Feb, 2018 US9919050
Dispatch to FDC 07 Feb, 2018 US9919050
Application Is Considered Ready for Issue 02 Feb, 2018 US9919050
Issue Fee Payment Received 01 Feb, 2018 US9919050
Issue Fee Payment Verified 01 Feb, 2018 US9919050
Mail Post Card 10 Nov, 2017 US9919050
Mail Notice of Allowance 02 Nov, 2017 US9919050


Meda Pharms's Drug Patent Litigations

Meda Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 07, 2014, against patent number US8071073. The petitioner Impax Laboratories, Inc., challenged the validity of this patent, with Meda Pharmaceuticals Inc. as the respondent. Click below to track the latest information on how companies are challenging Meda Pharms's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8071073 May, 2014 Terminated-Denied
(29 Jul, 2014)
Meda Pharmaceuticals Inc. Impax Laboratories, Inc.


Meda Pharms's Family Patents

Meda Pharms drugs have patent protection in a total of 24 countries. It's US patent count contributes only to 16.4% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Meda Pharms Drug List

Given below is the complete list of Meda Pharms's drugs and the patents protecting them.


1. Astepro

Astepro is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8071073 Compositions comprising azelastine and methods of use thereof 04 Jun, 2028
(3 years from now)
Active
US8518919 Compositions comprising azelastine and methods of use thereof 22 Nov, 2025
(1 year, 1 month from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Astepro's drug page


2. Reglan Odt

Reglan Odt is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6024981 Rapidly dissolving robust dosage form 09 Apr, 2018
(6 years ago)
Expired
US6221392 Rapidly dissolving robust dosage form 09 Apr, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reglan Odt's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List